Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice

Reumatologia Clinica

Volumn 5, Issue 6, 2009, Pages 252-258

  Ferraz Amaro, Iván ^a   Machín, Sergio ^b   Carmona, Loreto ^c   González Alvaro, Isidoro ^d   Díaz González, Federico ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b Hospital Insular de Lanzarote   (Spain)

^c UNIDAD DE INVESTIGACIÓN   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Adverse effects; Cohort studies; Nonsteroidal anti inflammatory drugs; Rheumatoid Arthritis

Indexed keywords

ACECLOFENAC; ANTIULCER AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALOPECIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG USE; DYSLIPIDEMIA; DYSPEPSIA; EPIGASTRIC PAIN; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; HYPERTENSION; HYPERTRANSMINEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METEORISM; NAUSEA; NEOPLASM; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; STOMACH DISEASE; STOMACH ULCER; TENESMUS; THROMBOCYTOPENIA; TINNITUS; VERTIGO;

EID: 70449530628     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2008.12.015     Document Type: Article

References (31)

1. Scott D.L., Symmons D.P., Coulton B.L., and Popert A.J. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1 (1987) 1108-1111
2. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46 (2002) 328-346
3. Gonzalez-Alvaro I., Hernandez-Garcia C., Villaverde Garcia V., Vargas E., and Ortiz A.M. Variations in the drug treatment of rheumatoid arthritis in Spain. Med Clin (Barc) 118 (2002) 771-776
4. Cush J.J., Lipsky P.E., Postlethwaite A.E., Schrohenloher R.E., Saway A., and Koopman W.J. Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum 33 (1990) 19-28
5. Olsen N.J., Callahan L.F., and Pincus T. In vitro rheumatoid factor synthesis in patients taking second-line drugs for rheumatoid arthritis. Independent associations with disease activity. Arthritis Rheum 31 (1988) 1090-1096
6. Díaz-González F., and Sánchez-Madrid F. Inhibition of leukocyte adhesion: an alternative mechanism of action for anti-inflammatory drugs. Immunol Today 19 (1998) 169-172
7. Dominguez-Jimenez C., Diaz-Gonzalez F., Gonzalez-Alvaro I., Cesar J.M., and Sanchez-Madrid F. Prevention of alphaII(b)beta3 activation by non-steroidal antiinflammatory drugs. FEBS Lett 446 (1999) 318-322
8. Kopp E., and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265 (1994) 956-959
9. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105 (1998) 31-38
10. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
11. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
12. Chan F.K., Hung L.C., Suen B.Y., Wu J.C., Lee K.C., Leung V.K., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
13. Psaty B.M., and Furberg C.D. COX-2 inhibitors--lessons in drug safety. N Engl J Med 352 (2005) 1133-1135
14. Strand V., and Hochberg M.C. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 47 (2002) 349-355
15. Balsa A., Carmona L., Gonzalez-Alvaro I., Belmonte M.A., Tena X., and Sanmarti R. Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 31 (2004) 40-46
16. Gonzalez-Alvaro I., Carmona L., Balsa A., Sanmarti R., Belmonte M.A., and Tena X. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 30 (2003) 697-704
17. Carmona L., Gonzalez-Alvaro I., Balsa A., Angel Belmonte M., Tena X., and Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 62 (2003) 897-900
18. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
19. Esteve-Vives J., Batlle-Gualda E., and Reig A. Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency. Grupo para la Adaptacion del HAQ a la Poblacion Espanola. J Rheumatol. 20 (1993) 2116-2122
20. Alonso J., Prieto L., and Anto J.M. The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc) 104 (1995) 771-776
21. Prevoo M.L., van 't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., and van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
22. Edmonds J., Saudan A., Lassere M., and Scott D. Introduction to reading radiographs by the Scott modification of the Larsen method. J Rheumatol 26 (1999) 740-742
23. Baum C., Kennedy D.L., and Forbes M.B. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 28 (1985) 686-692
24. Hamerman D. Clinical implications of osteoarthritis and ageing. Ann Rheum Dis 54 (1995) 82-85
25. Justice E., and Carruthers D.M. Cardiovascular risk and COX-2 inhibition in rheumatological practice. J Hum Hypertens 19 (2005) 1-5
26. Isomaki H., Martio J., Kaarela K., Kajander A., Koota K., Lehtinen K., et al. Comparison of the analgesic effect of ten nonsteroidal anti-inflammatory drugs. Br J Rheumatol 23 (1984) 61-65
27. Johnson A.G., Nguyen T.V., and Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121 (1994) 289-300
28. Solomon D.H., Karlson E.W., Rimm E.B., Cannuscio C.C., Mandl L.A., Manson J.E., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107 (2003) 1303-1307
29. Laine L., Harper S., Simon T., Bath R., Johanson J., Schwartz H., et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117 (1999) 776-783
30. Mamdani M., Juurlink D.N., Kopp A., Naglie G., Austin P.C., and Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 328 (2004) 1415-1416
31. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120 (2001) 594-606